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Abstract: MET is a versatile receptor tyrosine kinase within the
human kinome which is activated by its specific natural ligand
hepatocyte growth factor (HGF). MET signaling plays an important
physiologic role in embryogenesis and early development, whereas
its deregulation from an otherwise quiescent signaling state in
mature adult tissues can lead to upregulated cell proliferation,
survival, scattering, motility and migration, angiogenesis, invasion,
and metastasis in tumorigenesis and tumor progression. Studies have
shown that MET pathway is activated in many solid and hemato-
logical malignancies, including lung cancer, and can be altered
through ligand or receptor overexpression, genomic amplification,
MET mutations, and alternative splicing. The MET signaling path-
way is known to be an important novel target for therapeutic
intervention in human cancer. A number of novel therapeutic agents
that target the MET/HGF pathway have been tested in early-phase
clinical studies with promising results. Phase 3 studies of MET
targeting agents have just been initiated. We will review the MET
signaling pathway and biology in lung cancer and the recent clinical
development and advances of MET/HGF targeting agents with
emphasis on discussion of issues and strategies needed to optimize
the personalized therapy and further clinical development.
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Molecular targeted therapy has been successfully appliedin the treatment of many human cancers, including lung
cancer.1 Epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs), gefitinib and erlotinib, have been
approved for advanced non-small cell lung cancer (NSCLC)
treatment in second- and third lines, and most recent data
providing strong rationale for first-line use in patients har-
boring EGFR-TKI sensitizing mutations (L858R and exon 19
deletions).2–6 Nonetheless, development of other novel mo-
lecular targeted therapy is still urgently needed to impact lung
cancer and improve survival. We now recognize that histo-
logically similar NSCLC indeed should not be considered as
one disease but a collection of heterogeneous molecular
disease subgroups with different underlying genetic/genomic
alterations. Hence, the quest for more novel targets to be
inhibited in lung cancer continues beyond EGFR. MET
receptor kinase has been under extensive basic and preclinical
investigation for over 25 years. MET is now known to be a
“druggable” target within the human kinome, with promising
results of early phase clinical investigations of MET targeting
agents emerging. This review will provide a concise sum-
mary of our current understanding of the biology, signaling,
targeted therapeutic agents, and the updated status of MET-
targeted clinical trial studies.
MET: STRUCTURE, FUNCTION, AND
SIGNALING
MET is a receptor tyrosine kinase (RTK) composed of
the -chain (50 kDa) and the transmembrane -chain (140
kDa) subunit linked by a disulphide bond. The cytoplasmic
tyrosine kinase domain contains a number of key serine and
tyrosine phosphorylation sites important in the recruitment of
SRC-homology-2-domain (SH2) containing signaling trans-
ducers and intermediaries. The representative functional
structures and domains of MET and its signaling cascades are
shown in Figure 1. The natural ligand for MET receptor is
hepatocyte growth factor (HGF), also called scatter factor
(SF), which is produced by stromal and mesenchymal cells
and acts primarily on MET-expressing epithelial cells in an
endocrine and/or paracrine fashion.7 It was originally identi-
fied as a mitogen for hepatocytes and motogen for epithelial
cells. HGF/MET autocrine activation in HGF-transgenic
mice or MET-transgenic mice in vivo with promotion of
hepatocarcinogenesis has also been reported.8–10 Upon ligand
binding to HGF, MET is phosphorylated at multiple residues
with subsequent catalytic activation of a multitude of signal-
ing cascade involved in cell proliferation, survival, angiogen-
esis, morphogenesis, cell scattering, motility, migration, and
invasion. Importantly, it is known to have pivotal functions in
embryogenesis and organogenesis under its physiological
genetic invasive programming.11 The phosphorylation of the
major autophosphorylation sites Y1230, Y1234, and Y1235,
located within the activation loop of the tyrosine kinase
domain, activates the intrinsic catalytic kinase activity of
MET. As a result, an activated docking site in the kinase
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FIGURE 1. MET receptor signaling and strategies of therapeutic inhibition in lung cancer. The natural ligand for MET is he-
patocyte growth factor (HGF), also called scatter factor (SF). Aberrant HGF stimulation of MET in human cancer can occur by
aberrant autocrine (intratumoral), paracrine (mircoenvironmental), or endocrine (circulatory) loop signal activation. Upon HGF
binding to the Sema domain, MET dimerizes leading to autophosphorylation of intracellular tyrosine residues Y1230/Y1234/
Y1235 followed by the phosphorylation of Y1349 and Y1356 near the carboxyl terminal portion. MET activation results in the
recruitment and activation of downstream adaptor proteins and kinase targets resulting in a multitude of effects such as in-
creased cell proliferation, cell cycle progression, scattering, motility, survival, extracellular matrix remodeling, and changes in
metabolism. Thus, MET signaling contributes to tumor growth, scattering, motility, invasiveness, and metastasis, thereby play-
ing important roles in mediating tumor addiction/dependence and tumor expedience. Therapeutic intervention strategies to
block and inhibit MET receptor oncogenic signaling cascade include blocking ligand-receptor interaction, preventing receptor
dimerization, blocking MET kinase intrinsic activity, and inhibiting specific downstream signal transducers. PI3K, phosphatidyl-
inositol 3-kinase; GRB2, growth factor receptor-bound protein 2; GAB1, Grb2-associated adaptor protein1; STAT 3/5, signal
transducer and activator of transcription 3/5; mTOR, mammalian target of rapamycin; SOS, son of sevenless; SHP2, SRC ho-
mology protein tyrosine phosphatase 2; SHC, SRC homology domain; PLC-, phospholipase c-; RAS, rat sarcoma oncogene
homolog; MAPK, mitogen-activated protein kinase; RAC1, Ras-related C3 botulinum toxin substrate 1; RHO, Ras homologos;
PAX, paxillin; FAK, focal adhesion kinase.
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domain further recruits intracellular adaptor molecules
through the SH2 domains and other recognition motifs, such
as GAB1 (key coordinator of the cellular responses to MET).
Downstream signaling of the GRB2-mitogen-activated pro-
tein kinase (MAPK) cascade, the PI3K-mTOR pathway, and
the STAT pathway are eventually activated, mediating vari-
ous cellular functions.12,13 MET is also known to cross-talk
with various signaling pathways.14 The cross-talk between
MET and EGFR/HER family receptors is particularly impor-
tant in lung cancer.15,16 The notion of cross-talk between
MET and KRAS signaling is also emerging with both pre-
clinical and clinical findings of high interest.17,18 Matsubara
et al.,19 in a study to determine molecular predictors of
sensitivity to the MET inhibitor PHA-665752 in lung carci-
noma cells, identified that high P-MET and dependence of the
AKT and ERK signaling pathways on MET activation may
predict drug sensitivity, especially in KRAS-mutated cell
lines. Furthermore, PHA-665752 has been shown to reverse
lung premalignancy induced by mutant-KRAS (KrasLA1
mice) in vivo.20
MET AMPLIFICATION, OVEREXPRESSION,
ALTERNATIVE SPLICING AND MUTATION,
AND PHOSPHORYLATION IN LUNG CANCER
MET/HGF axis is essential in embryogenic develop-
ment of placenta, liver, kidney, neurons, and muscle.11 In
vivo, the MET receptor triggers a unique biological program
leading to “invasive growth, ” a phenomena including cell
proliferation, scattering, survival, motility and invasion, epi-
thelial-mesenchymal transition (EMT), and branched mor-
phogenesis.21,22 Studies have shown that MET alterations
occur in numerous human solid and hematological malignan-
cies (http://www.vai.org/met). MET pathway has been found
to be activated in a number of human malignancies, including
lung cancer. MET can be altered through receptor overex-
pression, genomic amplification, mutations, or alternative
splicing. These alterations lead to signaling deregulation
which can be mediated through ligand (HGF)-independent
receptor activation or through its ligand (HGF)-dependent
activation via autocrine (intratumoral HGF), paracrine (mes-
enchymal or microenvironmental HGF), or endocrine (circu-
latory HGF) loop signaling cascades (Fig. 1).
MET receptor is overexpresssed in both SCLC and
NSCLC (particularly in nonsquamous NSCLC).23–25 Recent
tumor microarray expression analysis of MET/HGF in human
cancers demonstrated that both MET and HGF are commonly
expressed in human solid cancers, including lung cancer.
Seventy-two percent (29 of 40) of lung cancer tissue was
found to express MET, and 40% (16 of 40) have MET
receptor overexpression.26 Moreover, phospho-MET expres-
sion is found to be the highest in lung cancer, followed by
ovarian, breast, renal, and colon cancers.26 Using a phospho-
proteomic approach, Rikova et al.27 characterized tyrosine
kinase signaling across 41 NSCLC cell lines and more than
150 NSCLC tumor samples and established that MET is the
topmost highly tyrosine-phosphorylated RTK in NSCLC tu-
mor samples (ranked third in cell lines). The study findings
lend further support to the role of MET as a primary “driver”
oncogenic kinase in NSCLC.
MET gene mutations and copy number variations have
been reported in a variety of human tumor tissues, especially
in lung cancer.22,25,26,28–32 The MET receptor mutations in
lung cancer were mainly found clustered in the nontyrosine
kinase domain, namely in the juxtamembrane (JM) domain
and sema domain. MET kinase domain mutations have been
found to be somatically selected in the metastatic tissues,
compared with the primary solid cancers.33 Previous studies
characterizing the JM domain mutations (R988C, T1010I,
alternative spliced JM-deleting variant) demonstrated that
these are oncogenic activating variants with enhanced onco-
genic signaling, tumorigenecity, cell motility, and migra-
tion.30,34 Both somatic and germline variants of MET have
been reported in various human cancers, including renal cell
carcinoma (in which MET kinase mutations were first iden-
tified both in hereditary and sporadic diseases) and thoracic
malignancies.30,33,34 Their relative significance and relevance
in lung cancer biology and progression remain to be further
defined. By using quantitative polymerase chain reaction
(QPCR) assay for MET amplification, multiple studies have
reported primary MET amplification to be in the wide range
of 2 to 21%, in NSCLC lung adenocarcinomas, particularly in
TKI-naive cohorts.28,29,31,32 By using the fluorescence in situ
hybridization (FISH) assay, the Lung Cancer Mutation Con-
sortium reported that 4.1% of adenocarcinoma (n  295)
haveMET amplification2.2 (defined by MET/CEP7), while
9.6% ALK 2p23 translocation was identified in ALK break-
apart FISH assay.35 Cappuzzo et al.36 tested MET gene copy
number in 447 NSCLC patients and found that high MET
gene copy number (5 copies/cell) was negatively associated
with survival (hazard ratio [HR]  0.66, p  0.04). On the
other hand, conflicting result was reported by Kanteti et al.29
who demonstrated that the MET gene copy number 4 in
lung adenocarcinoma tissue samples was associated with a
trend of better prognosis (median survival: 39 versus 16
months, p  0.06), albeit with a small sample size in the study.
Of note, this study was performed using QPCR method, but not
FISH, on DNA samples extracted from formalin-fixed paraffin-
embedded (FFPE) archival tumor tissues.
MET EXPRESSION: STEM/PROGENITOR CELLS
AND TUMOR HYPOXIA
HGF and MET are highly expressed in various stem
and progenitor cells, but only expressed in low levels in their
mature cells, indicating their important physiologic role in
cell differentiation and normal embryonic development.11
The concept of cancer stem cell (CSC) has been strengthened
in several instances through the identification and isolation of
CSCs from leukemia, breast and lung carcinomas, and tumors
of the central nervous system.37 MET has been postulated to
be a potential marker of an expanding cell population that is
undergoing an aberrant differentiation program and that re-
tains stem cell properties.37,38 MET expression was found to
co-localize at the lung bronchioalveolar duct junction where
the bronchioalveolar stem cells were identified.26,39 Recently,
De Bacco et al.40 reported an increased MET expression found
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in response to ionizing radiation through the ATM-NFB sig-
naling pathway, leading to radioresistance and cancer invasion.40
Hence, it is of high interest to ascertain whether MET expression
indeed is elevated in CSCs and contributes to CSC-mediated
therapeutic resistance and invasion.41
Hypoxia in tissue favors both stemness and invasive
growth in normal embryonic development and also in tumor
growth. It has been shown that hypoxia-induced MET ex-
pression and activation via hypoxia inducible factor-1 me-
diated transcriptional upregulation and amplified HGF sig-
naling, resulting in MET-HGF-synergized induction of
invasion. The inhibition of MET expression prevented hy-
poxia-induced invasion growth.42
ROLE OF MET-HGF IN EGFR-TKI RESISTANCE
IN LUNG CANCER
The EGFR-TKIs gefitinib and erlotinib have demon-
strated efficacies in NSCLC, particularly with EGFR activa-
tion mutations. Nonetheless, invariable acquired resistance
remains a formidable challenge that ultimately leads to pa-
tient’s mortality. Using in vitro cell line model, Engelman et
al.43 demonstrated the emergence of MET gene amplification
in EGFR-TKI-resistant cell clones (HCC827-GR) derived
upon chronic escalating gefitinib exposure. MET amplifica-
tion was observed in 4 of 18 (22%) lung cancer specimens
with acquired EGFR-TKI resistance,43 a result that was con-
firmed in another study by Cappuzzo et al. also.44 Bean et
al.45 reported a similar MET amplification rate (9/43, 21%) in
patients with acquired EGFR-TKI resistance, compared with
only 3% (2/62) in untreated EGFR-mutant patients. Nonethe-
less, 44% (4/9) patients found with MET amplification also
had concurrent T790M-EGFR-resistant mutation, raising
queries about the relative role of the two alterations in
mediating EGFR-TKI resistance. Of note, two most recent
tissue rebiopsy studies on genetic analysis of acquired EGFR-
TKI-resistant NSCLC reported 11% (4/37) and 5% (2/37) of
samples found with MET high gene copy number, frequen-
cies that are somewhat lower than anticipated based on earlier
data.46,47 Rho et al.48 demonstrated that MET activation,
instead of MET gene amplification, in PC-9 EGFR-TKI-
resistant cells, and sustained activation of MET by HGF-
enhanced tumor cell migration and invasion abilities. How-
ever, their work showed that the MET activation was
secondary to increasing passage number without exposure to
EGFR-TKI and was not related to EGFR-TKI resistance.48
Our previous study demonstrated that in erlotinib-resistant
H1975 lung adenocarcinoma cells (T790M/L858R-EGFR)
expressing wild-type MET without genomic amplification,
SU11274 (MET inhibitor) alone and even better when in
combination with erlotinib effectively inhibited H1975
cells with enhanced abrogation of cytoskeletal functions
and regression of the xenograft growth.16 Together, the
studies above provide a rationale to develop clinical stud-
ies of MET inhibitor, alone and in combination with
EGFR-TKI in NSCLC (especially TKI-resistant patients),
both as primary or secondary strategies to prevent or
overcome EGFR-TKI resistance.
With in vitro and in vivo evidence, we recently showed
that drug-sensitive cells with mutant EGFR (HCC827, PC-9
[with deletion exon 19] against erlotinib and H1975 [with
L858R/T790M] against CL-387,785) exhibited a very early,
within the first 6 to 9 days of drug exposure, “adaptive” tumor
resistance to escape the EGFR-TKIs, implicating a model of
“minimal residual disease.”49 Most interestingly, these cells
that existed in a quiescence state evaded the TKIs through
MET-independent survival mechanism with newly addicted
dependence on the mitochondrial BCL-2/BCL-xL antiapop-
totic pathway, which can be further targeted by BH3-mimetic
agents to inhibit the BCL-2/BCL-xL signal path.49 Hence, the
role of MET in acquired EGFR-TKI resistance might be more
relevant in the late stages of resistance development but not
necessarily so in the early emergence of adaptive drug resis-
tance state.
CURRENT CLINICAL DATA OF MET INHIBITORS
IN LUNG CANCER
Preclinical MET Inhibitors
Early preclinical MET inhibitors that have been
studied include geldanamycin, K252a, SU11274, and PHA-
665752.18,25,50,51 It has been demonstrated that small molecule
MET inhibitors SU11274 and PHA-665752 inhibited cell
viability and growth and induced apoptosis by inhibiting
MET/HGF signaling on various NSCLC cell lines.16,18,20,25
Tivantinib (ARQ197; ArQule/Daiichi-Sankyo)
Currently, there are many MET-targeting agents, in-
cluding small molecules and antibodies that are under devel-
opment (Table 1). Seven of them have been approved for
human clinical trials. Among them, tivantinib is the only one
currently in phase 3 trial. It is uniquely the first non-ATP–
competitive small molecule that selectively targets the MET
RTK, with the mechanism of action as locking the kinase in
a “closed” and “inactive” conformation when bound to the
drug. In vivo study demonstrated its antitumor activity in
various cancers (colon, gastric, and breast cancers).52 Tivan-
tinib is mainly metabolized by CYP2C19. The ratio of the
poor metabolizer (PM) of CYP2C19 in Asians is reported to
be around 20%, while it is very low in Caucasians. A phase
I trial in Japanese found that tivantinib was well tolerated in
PM patients as well as extensive metabolizer (EM) patients.
CYP2C19 genotypes clearly affected the exposure to tivan-
tinib, a finding that led to different recommended phase 2
doses: 360 mg twice a day for EM patients and 240 mg twice
a day for PM patients.53 A number of phase 2 trials have been
launched to investigate the effects of ARQ197 in various
malignancies, including lung cancer. ARQ197-209 is a global
randomized placebo-controlled phase 2 clinical trial compar-
ing erlotinib (150 mg) plus ARQ197 (360 mg, twice a day)
(E  A) versus erlotinib plus placebo (E  P) in advanced
NSCLC patients. Primary end point is progression-free sur-
vival (PFS), and secondary end points are overall response
rate, overall survival, and subset analysis. The trial result was
presented in the 2010 American Society of Clinical Oncology
(ASCO) meeting. The trial enrolled 167 patients who were
randomized to E  A (84 patients) or E  P (83 patients).
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Final PFS was prolonged with E  A versus E  P (median:
16.1 versus 9.7 weeks, HR 0.81, p  0.23). Planned multi-
variable Cox regression model adjusting for prognostic fac-
tors yielded PFS HR 0.68 (95% CI 0.47–0.98, p 0.05). The
subgroup analyses showed that PFS was significantly better
in ARQ197 arm in patients with KRAS mutant (median PFS:
2.3 versus 1.0 months, HR  0.18, p  0.05), and similar
trend (not statistically significant) in patients with nonsqua-
mous cell and EGFR wild type. The side effects, including
rash, diarrhea, fatigue, and anemia, were similar in two
groups.54 Interestingly, ARQ197 combined with erlotinib was
also found to inhibit tumor metastases in this phase 2 study,
consistent with the notion of theMET “oncogene expedience”
that can be targeted.
A global randomized phase 3 trial (MARQUEE) of
ARQ197 in combination with erlotinib, versus erlotinib plus
placebo, for advanced nonsquamous NSCLC who have re-
ceived one or two prior systemic anticancer therapies is now
ongoing. There is also a parallel randomized phase 3 study in
Asia (Japan, Korea, Taiwan) (ARQ197-006) for wild-type
EGFR advanced nonsquamous NSCLC with E  A versus
E P arms which doses ARQ197 according to the CYP2C19
polymorphism (ATTENTION, NCT 01377376), already
started recruiting since June 2011. In addition, a phase 2 ran-
domized open-label study of erlotinib plus ARQ197 (E  A)
versus single-agent chemotherapy in previously treated KRAS
mutation-positive patients with locally advanced or metastatic
NSCLC (ARQ197-218) has just been started in July 2011
(NCT01395758). This trial has the primary objective to evaluate
median PFS among subjects with KRAS mutation-positive
NSCLC (intent-to-treat population) treated with E  A com-
pared with single-agent chemotherapy.
Cabozantinib (XL184/BMS-907351; Exelixis/
Bristol Myer Squibb)
Cabozantinib, a multitargeted inhibitor with activities
against MET/VEGFR2/RET, has been studied in a phase 1b/2
trial with and without erlotinib (E) in patients with NSCLC in
patients with acquired erlotinib resistance.55 The trial was
previously reported in 2010 ASCO. The overall safety and
tolerability profile of cabozantinib and erlotinib appear ac-
ceptable without evidence of a cabozantinib/erlotinib drug-
drug interaction. Six of 36 patients assessable for response
including at least 3 with prior erlotinib therapy had 30%
reduction in tumor measurements on at least 1 postbaseline
scan, including 3 with a complete or partial response (PR)
(1 with MET amplification). Prolonged stable disease (SD)
4 months has been observed in some patients including one
for more than 9 months and one with EGFR T790M.55
The phase 2 randomized discontinuation trial of cabo-
zantinib (XL184) in patients with advanced solid tumors has
been completed and the interim result was recently presented
in ASCO 2011 Annual Meeting.56 398 of 483 enrolled pa-
tients with nine different types solid tumors were evaluable,
and evidence of soft tissue tumor regression was observed in
all tumor types. Most common related adverse events (grade
3) were fatigue (9%), hand-foot syndrome (8%), and HTN
(5%). Dose reductions for adverse events occurred in 41%
patients. Rate of overall disease control (PR or SD) at week
12 of 40% or higher were observed in six different solid
tumors, including NSCLC (40%, PR 6/47, 13%). Interest-
ingly, all the patients with EGFR (4/23) or KRAS (3/23)
mutations had PR or SD, and none of the nonresponders had
EGFR or KRAS mutations. However, the sample size is too
small to draw any conclusion between the response rate and
EGFR/KRAS mutation status. The MET amplification status
was not reported in this interim report. Quite interestingly,
there were soft tissue and visceral tumor regression and
resolution of bone lesions on bone scan observed across
multiple tumor types, supporting the notion of targeting
MET pathway as the player of “oncogene addiction/depen-
dence” and “oncogene expedience.”56
Foretinib (XL880, EXEL-2880, GSK1363089;
Exelixis/GSK)
Foretinib is a multitargeted small-molecule kinase in-
hibitor that targets MET and members of the VEGF receptor
kinase families, with additional inhibitory activity toward
KIT, FLT-3, PDGFR , Tie-2, RON, and AXL.57 In vivo,
these effects produce significant dose-dependent inhibition of
tumor burden in an experimental model of lung metastasis.57
A phase1 study of foretinib has been conducted in metastatic
TABLE 1. Examples of c-MET Inhibitory Agents
Targets Company Phase
Tivantinib (ARQ 197) MET (non-ATP competitive) ArQule/Daiichi-Sankyo Phase 1/2–3
Crizotinib (PF-2341066) MET, ALK Pfizer Phase 1/2–3
MetMAb MET (one-arm MAb) Genentech/Roche Phase 2
Ficlatuzumab (AV-299) HGF Ab AVEO Phase 2
Foretinib (XL880, EXEL-2880, GSK1363089 MET, VEGFR2, AXL Exelixis/GSK Phase 1/2
Cabozantinib (XL184, BMS-907351) MET, RET, VEGFR2 Exelixis/BMS Phase 1/2
PF-04217903 MET Pfizer Phase 1
SGX523 MET SGX Phase 1
AMG 102 HGF (Hu MAb) Amgen Phase 1
CE-355621 MET (MAb) Pfizer Preclinical
Xcovery MET-I MET Xcovery Preclinical
SGX126 MET SGX Preclinical
MGCD265 MET MethylGene Preclinical
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or unresectable solid tumor patients.58 A phase 1/2 clinical
trial of GSK1363089 versus GSK1363089 and erlotinib in
locally advanced or metastatic NSCLC is currently ongoing.
MetMAb (Genentech-Roche)
Several MET/HGF antibodies have also been devel-
oped for targeting the pathway. MetMAb is a recombinant,
humanized, monovalent (one-armed) monoclonal antibody
antagonist of the MET receptor to achieve targeted inhibition
of the ligand HGF-induced MET signaling. Its safety and
recommended dose has been established in patients with solid
tumor in a phase1b trial.59 Recently, a global randomized,
double-blind phase 2 study comparing MetMAb  erlotinib
(ME) to placebo  erlotinib (PE) in second-/third-line
NSCLC (OAM4558g) has been completed. The updated
efficacy results were presented in ASCO 2011 Annual Meet-
ing. One hundred twenty-eight NSCLC patients were equally
randomized to receive ME or PE. Fifty-four percent (54%) of
patients had MET immunohistochemistry (IHC) expression
(2 or 3) NSCLC, which was associated with a worse
outcome (OS HR  2.52, PE cohort). In the METIHC 2 or
3 group (N  65), ME resulted in a statistically and
clinically significant improvement in both PFS (median 3.0
versus 1.5 months, HR  0.47, p  0.01) and OS (median
12.6 versus 4.6 months, HR  0.37, p  0.002).60 In
MET-IHC low/negative group, the OS was worse in ME than
PE group (HR  3.02, p  0.021). E-related toxicities were
comparable between treatment arms. The design of MetMAb
phase 2 trial incorporating the development of a companion
diagnostic test for assaying MET receptor expression level by
IHC is worthy of merits. In the MetMAb trial, according to
the trial investigators, the overall survival benefit (or the trend of
OS benefit) was not exclusive to EGFR mutations or MET
FISH (5 copies)(p  0.19) and was observed in FISH/
IHC (p  0.09) patients, suggesting that IHC is a more
sensitive predictor of benefit from MetMAb. Removing patients
with EGFRmutations did not alter results, albeit with the p value
of survival benefit becoming statistically insignificant (p 0.29)
in the analysis likely due to a small sample size.60
These results lend support for further investigation of
MetMAb as a potential personalized MET-targeting cancer
therapeutics for NSCLC patients, and a phase 3 study is being
planned currently. Nonetheless, in light of the negative sur-
vival data seen in the ME arm in patients with low MET
expression in the phase 2 study, and despite a lack of obvious
and satisfactory mechanistic explanation for the observation,
the phase 3 study would likely be only limiting to the
inclusion of MET-expressing patients.
Crizotinib (PF-2341066, Pfizer)
Crizotinib has very recently been approved by the Food
and Drug Administration in the United States for patients
with NSCLC whose tumor harbors EML4-ALK gene fusion as
determined by the parallelly approved Vysis LSI dual color
probe ALK 2p23 break-apart rearrangement FISH assay (Ab-
bott). Crizotinib has known MET kinase inhibitory activity in
addition to that of ALK. Interestingly, the drug was initially
developed intending as a MET inhibitor preclinically and
subsequently in a phase 1 trial.61,62 It potently inhibited MET
phosphorylation and MET-dependent proliferation, migra-
tion, or invasion of human tumor cell in vitro. In addition, it
also potently inhibited HGF-stimulated endothelial cell sur-
vival or invasion and serum-stimulated tubulogenesis in vitro,
indicating that its cytoreductive antitumor efficacy may be
mediated by direct effects on tumor cell growth or survival as
well as antiangiogenic mechanisms.63 Subsequently, the clin-
ical development of crizotinib was steered toward focusing
primarily on ALK-rearranged NSCLC, ultimately leading to
the drug’s recent Food and Drug Administration approval in
August 2011. However, in a recent case report, a NSCLC
patient with de novo MET amplification but no ALK rear-
rangement achieved a rapid and durable response to crizo-
tinib, indicating that it is also a bona fide MET inhibitor
clinically.64 Dramatic clinical improvement and radiographic
regression were also observed in patients withMET-amplified
esophagogastric adenocarcinoma65 and glioblastoma multi-
forme66 upon treatment with crizotinib.
Others
A growing list of other MET or HGF targeting agents
continues to emerge, and some of the agents are currently still
under preclinical and early clinical development, as listed in
Table 1 and Figure 1.
STRATEGIES FOR OPTIMIZED MET-TARGETED
PERSONALIZED LUNG CANCER THERAPY
The role of MET/HGF in cancer growth and invasion
has been extensively studied, and the recent clinical studies
on MET inhibitor or antibody in malignancy including
NSCLC are quite promising. However, a number of impor-
tant questions remain to be fully answered in the optimization
of MET target therapy as outlined below. Addressing these
critical areas of MET inhibition strategies in lung cancer
would help to bring MET-targeted agents to full clinical
fruition to meaningfully impact patient outcomes.
1. Should MET targeted inhibition be developed as pri-
mary or secondary strategies in the context of mutated
EGFR and wild-type EGFR lung cancer patients? Cur-
rent studies testing MET agents have both been con-
ducted in primary inhibition strategy (tivantinib, Met-
MAb) and in secondary strategy (cabozantinib) to
overcome acquired EGFR TKI resistance, in combina-
tion with erlotinib. Emerging data implicate that MET
inhibition either alone or in combination with EGFR-
TKI may indeed have a role in primary therapy for
EGFR-TKI-naive NSCLC patients.
2. Can we identify biomarker of response to MET inhibi-
tion? The optimal patient subgroup that would benefit
from single-agent MET inhibitor treatment remains to
be determined. Further effort to better define the mo-
lecular determinants of MET therapy response would be
needed to unleash the full impact of the targeted ther-
apeutics. Beyond MET genomic amplification as poten-
tial predictive biomarker, MET overexpression, HGF
status, MET mutations, and cross-talk partners, e.g.,
EGFR and KRAS, would all be worthy of further
investigations here. To this end, newer venues of bioin-
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formatics and pathway analysis may be of benefit to
achieve these goals, especially when incorporated into
upcoming future MET agents clinical studies.
3. Can we inhibit MET to target oncogene expedience? It
is attractive to further test the notion of inhibiting MET
with targeting inhibitors in human cancers to abrogate
or delay MET-driven cancer invasion and metastasis in
disease progression. Emerging clinical trial data from
the tivantinib phase 2 study in combination with erlo-
tinib54 and also the cabozantinib randomized discontin-
uation phase 2 trial study56 highlighted the potential in
inhibiting MET-driven oncogene expedience in impact-
ing on tumor progression and metastasis. Further pre-
clinical modeling and clinical trial design incorporating
this question for validation would be warranted.
4. Can we optimize combinational MET therapy with
other targeted agents? A number of potential opportu-
nities exist in this regard which require further testing
and validation. Examples for rational combination ther-
apy include HGF targeting agents, EGFR TKIs, other
targeted kinases agents, or downstream signaling effec-
tor inhibitors, e.g., PI3K-I, MEK-I, BCL-2/BCL-xL
inhibitor (BH3 mimetic).
5. What are the potential acquired resistance mechanisms
against MET targeting inhibition? Prior experience in
other targeted therapeutics, such as erlotinib against
mutant EGFR and crizotinib against EML4-ALK, sug-
gests that acquired resistance is thus far unavoidable
despite initial response. Proactive efforts in identifying
potential resistance mechanisms in MET-targeted inhi-
bition would be needed to accelerate the discovery of
newer cotargeting strategies to dampen drug resistance.
Efforts to derive a deeper understanding of tumor biol-
ogy and molecular pathways in progressing disease
from rebiopsy tissues in sites of resistant disease could
have profound impact in advancing our rational thera-
peutic strategies in MET-targeting therapy.
FUTURE PERSPECTIVES
The important role of MET pathway in various malig-
nancies including lung cancer has been demonstrated in
extensive preclinical studies. Studies also support MET as an
attractive druggable target, as seen in various recent early-
phase clinical trial studies. The clinical efficacy of MET-
targeting agents in lung cancer will need be ultimately tested
in phase 3 randomized studies, some of which are already
ongoing (tivantinib, MetMAb). However, to fully impact the
clinical outcome in lung cancer in using MET targeting
therapeutics, a number of questions remain to be further
addressed. What constitutes MET-driven/dependent lung
cancer, in terms of addiction/dependence and expedience? Is
there a role for MET monotargeting therapy, and when,
versus combination therapy with EGFR TKI and others?
What are the molecular determinants of response, as predic-
tive biomarkers, to MET agents (might differ in different
drugs with varying mechanisms of action)?
To this end, studies on the biomarkers to predict MET
inhibitor sensitivities are beginning to show promise. MET
amplification has been shown to correlate with drug sensitiv-
ity in preclinical models.67 MET overexpression as deter-
mined by IHC staining is showing great promise as illustrated
by the MetMAb phase 2 study results, and further work in
developing this as a companion diagnostic test is only certain.
Optimizing and standardizing MET expression and amplifi-
cation analysis, whether FISH, QPCR, FFPE, or IHC, would
be crucial in the future clinical development. More novel
technological platforms might be useful in this regard, as in
the example of multiplexed expression assays and FFPE-
LCM mass spectrometry-based quantitative tissue proteom-
ics. Better and more sophisticated bioinformatics algorithm
would be highly helpful in defining MET activation and thus
molecular candidate patient selection. Moreover, noninvasive
in vivo MET expression in murine xenograft model by using
[C11]SU11274-PET imaging68 also shows promise in devel-
oping an imaging platform of clinical utilities in molecular-
targeting patient selection and in monitoring therapeutic re-
sponse and progression under MET inhibitor therapy. With
concerted efforts in translational and clinical development of
the MET-targeting agents to continue, it will not be unreal-
istic to expect MET-targeting therapies to finally come to full
clinical fruition in the foreseeable future to impact on lung
cancer clinical outcome.
REFERENCES
1. Ray MR, Jablons D, He B. Lung cancer therapeutics that target signaling
pathways: an update. Expert Rev Respir Med 2010;4:631–645.
2. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-
paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–
957.
3. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as
first-line treatment for patients with advanced EGFR mutation-positive
non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre,
open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735–742.
4. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy
for non-small-cell lung cancer with mutated EGFR. N Engl J Med
2010;362:2380–2388.
5. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring muta-
tions of the epidermal growth factor receptor (WJTOG3405): an open
label, randomised phase 3 trial. Lancet Oncol 2010;11:121–128.
6. Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versus chemother-
apy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p)
with epidermal growth factor receptor (EGFR) mutations: interim results
of the European Erlotinib Versus Chemotherapy (EURTAC) phase III
randomized trial. J Clin Oncol 2011;29(Suppl):Abstr 7503.
7. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and
invasion-metastasis by hepatocyte growth factor/scatter factor-met sig-
nalling in human cells concomitant with induction of the urokinase
proteolysis network. Mol Cell Biol 1996;16:1115–1125.
8. Horiguchi N, Takayama H, Toyoda M, et al. Hepatocyte growth factor
promotes hepatocarcinogenesis through c-Met autocrine activation and
enhanced angiogenesis in transgenic mice treated with diethylnitro-
samine. Oncogene 2002;21:1791–1799.
9. Tward AD, Jones KD, Yant S, et al. Distinct pathways of genomic
progression to benign and malignant tumors of the liver. Proc Natl Acad
Sci USA 2007;104:14771–14776.
10. Wang R, Ferrell LD, Faouzi S, et al. Activation of the Met receptor by
cell attachment induces and sustains hepatocellular carcinomas in trans-
genic mice. J Cell Biol 2001;153:1023–1034.
11. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its
receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998;8:404–410.
12. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site
mediates signaling and transformation by the hepatocyte growth factor/
scatter factor receptor family. Cell 1994;77:261–271.
Journal of Thoracic Oncology • Volume 7, Number 2, February 2012 Targeted MET Inhibition
Copyright © 2012 by the International Association for the Study of Lung Cancer 465
13. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility
and more. Nat Rev Mol Cell Biol 2003;4:915–925.
14. Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis.
Trends Cell Biol 2009;19:542–551.
15. Guo A, Villen J, Kornhauser J, et al. Signaling networks assembled by
oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008;105:692–
697.
16. Tang Z, Du R, Jiang S, et al. Dual MET-EGFR combinatorial inhibition
against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J
Cancer 2008;99:911–922.
17. Long IS, Han K, Li M, et al. Met receptor overexpression and oncogenic
Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer
cells in vivo. Mol Cancer Res 2003;1:393–401.
18. Ma PC, Schaefer E, Christensen JG, et al. A selective small molecule
c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer
Res 2005;11:2312–2319.
19. Matsubara D, Ishikawa S, Oguni S, et al. Molecular predictors of
sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
J Thorac Oncol 2010;5:1317–1324.
20. Yang Y, Wislez M, Fujimoto N, et al. A selective small molecule
inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced
by mutant K-ras. Mol Cancer Ther 2008;7:952–960.
21. Comoglio PM. Pathway specificity for Met signalling. Nat Cell Biol
2001;3:E161–E162.
22. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and
potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:
309–325.
23. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation
of hepatocyte growth factor/scatter factor in human non-small-cell lung
carcinomas. Br J Cancer 1996;74:1862–1868.
24. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte
growth factor pathway in small cell lung cancer. Clin Cancer Res
2002;8:620–627.
25. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and
mutations of c-Met and its therapeutic inhibition with SU11274 and
small interfering RNA in non-small cell lung cancer. Cancer Res
2005;65:1479–1488.
26. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and muta-
tional analysis of MET in human solid cancers. Genes Chromosomes
Cancer 2008;47:1025–1037.
27. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine
signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:
1190–1203.
28. Beau-Faller M, Ruppert AM, Voegeli AC, et al. MET gene copy number
in non-small cell lung cancer: molecular analysis in a targeted tyrosine
kinase inhibitor naive cohort. J Thorac Oncol 2008;3:331–339.
29. Kanteti R, Yala S, Ferguson MK, et al. MET, HGF, EGFR, and PXN
gene copy number in lung cancer using DNA extracts from FFPE
archival samples and prognostic significance. J Environ Pathol Toxicol
Oncol 2009;28:89–98.
30. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small
cell lung cancer: novel juxtamembrane domain mutations regulating
cytoskeletal functions. Cancer Res 2003;63:6272–6281.
31. Onitsuka T, Uramoto H, Ono K, et al. Comprehensive molecular
analyses of lung adenocarcinoma with regard to the epidermal growth
factor receptor, K-ras, MET, and hepatocyte growth factor status. J Tho-
rac Oncol 2010;5:591–596.
32. Onozato R, Kosaka T, Kuwano H, et al. Activation of MET by gene
amplification or by splice mutations deleting the juxtamembrane domain
in primary resected lung cancers. J Thorac Oncol 2009;4:5–11.
33. Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the
MET oncogene are selected during metastatic spread of human HNSC
carcinomas. Oncogene 2000;19:1547–1555.
34. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to
an oncogenic deletion of met in lung cancer. Cancer Res 2006;66:
283–289.
35. Varella-Garcia M, Iafrate J, Pao W, et al. ALK fusion and MET
amplification as molecular biomarkers and therapeutic targets in ad-
vanced lung adenocarcinomas in the Lung Cancer Mutation Consortium.
14th World Conference on Lung Cancer, Amsterdam, The Netherlands,
July 3–7, 2011.
36. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy
number negatively affects survival of surgically resected non-small-cell
lung cancer patients. J Clin Oncol 2009;27:1667–1674.
37. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic
programme for cancer and stem cells. Nat Rev Cancer 2006;6:637–645.
38. Li Y, Li A, Glas M, et al. c-Met signaling induces a reprogramming
network and supports the glioblastoma stem-like phenotype. Proc Natl
Acad Sci USA 2011;108:9951–9956.
39. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchio-
alveolar stem cells in normal lung and lung cancer. Cell 2005;121:823–
835.
40. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing
radiation and its role in radioresistance and invasive growth of cancer.
J Natl Cancer Inst 2011;103:645–661.
41. Guryanova OA, Bao S. How scatter factor receptor c-MET contributes
to tumor radioresistance: ready, set, scatter! J Natl Cancer Inst 2011;
103:617–619.
42. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes
invasive growth by transcriptional activation of the met protooncogene.
Cancer Cell 2003;3:347–361.
43. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification
leads to gefitinib resistance in lung cancer by activating ERBB3 signal-
ing. Science 2007;316:1039–1043.
44. Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy
number and primary resistance to gefitinib therapy in non-small-cell
lung cancer patients. Ann Oncol 2009;20:298–304.
45. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or
without T790M mutations in EGFR mutant lung tumors with acquired
resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:
20932–20937.
46. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients
with acquired resistance to EGFR inhibitors and enhanced detection of
the T790M mutation using a locked nucleic acid-based assay. Clin
Cancer Res 2011;17:1169–1180.
47. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and
histological evolution of lung cancers acquiring resistance to EGFR
inhibitors. Sci Transl Med 2011;3:75ra26.
48. Rho JK, Choi YJ, Lee JK, et al. The role of MET activation in
determining the sensitivity to epidermal growth factor receptor tyrosine
kinase inhibitors. Mol Cancer Res 2009;7:1736–1743.
49. Fan W, Tang Z, Yin L, et al. Met-independent lung cancer cells evading
EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic
agents. Cancer Res 2011;71:4494–4505.
50. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor
induces apoptosis in cells transformed by the oncogenic TPR-MET
tyrosine kinase. Cancer Res 2003;63:5462–5469.
51. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule
inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro
and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;
63:7345–7355.
52. Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor
of the human c-Met receptor tyrosine kinase with antitumor activity.Mol
Cancer Ther 2010;9:1544–1553.
53. Nishina T, Hirashima T, Sugio K, et al. The effect of CYP2C19
polymorphism on the tolerability of ARQ 197: results from phase I trial
in Japanese patients with metastatic solid tumors. J Clin Oncol 2011;
29(Suppl):Abstr 2516.
54. Schiller JH, Akerley WL, Brugger W, et al. Results from ARQ 197-209:
a global randomized placebo-controlled phase II clinical trial of erlotinib
plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR
inhibitor-naive patients with locally advanced or metastatic non-small
cell lung cancer (NSCLC). J Clin Oncol 2010;28(18S):Abstr LBA7502.
55. Wakelee HA, Gettinger SN, Engelman JA, et al. A phase Ib/II study of
XL184 (BMS 907351) with and without erlotinib (E) in patients (pts)
with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15S):
Abstr 3017.
56. Gordon MS, Vogelzang NJ, Schoffski P, et al. Activity of cabozantinib
(XL184) in soft tissue and bone: results of a phase II randomized
discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
J Clin Oncol 2011;29(Suppl):Abstr 3010.
57. Qian F, Engst S, Yamaguchi K, et al. Inhibition of tumor cell growth,
invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel
Feng et al. Journal of Thoracic Oncology • Volume 7, Number 2, February 2012
Copyright © 2012 by the International Association for the Study of Lung Cancer466
inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res
2009;69:8009–8016.
58. Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a
multi-targeted inhibitor of c-Met and vascular endothelial growth factor
receptor 2. Clin Cancer Res 2010;16:3507–3516.
59. Berinstein NL, Morse M, Kaufman H, et al. A phase I study of the safety
and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with
advanced-stage ovarian, breast, or prostate cancer. J Clin Oncol 2011;
29(Suppl):Abstr e13050.
60. Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from
OAM4558g, a randomized phase II study evaluating MetMAb or pla-
cebo in combination with erlotinib in advanced NSCLC. J Clin Oncol
2011;29(Suppl):Abstr 7505.
61. Cui JJ, Tran-Dube M, Shen H, et al. Structure based drug design of
crizotinib (PF-02341066), a potent and selective dual inhibitor of mes-
enchymal-epithelial transition factor (c-MET) Kinase and anaplastic
lymphoma kinase (ALK). J Med Chem 2011;54:6342–6363.
62. Kwak E, Camidge D, Clark J, et al. Clinical activity observed in a phase
I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066.
J Clin Oncol 2009;27(15 Suppl):Abstr 3509.
63. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule
inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor effi-
cacy through antiproliferative and antiangiogenic mechanisms. Cancer
Res 2007;67:4408–4417.
64. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib
(PF02341066), a dual mesenchymal-epithelial transition (MET) and
anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung
cancer patient with de novo MET amplification. J Thorac Oncol 2011;
6:942–946.
65. Lennerz J, Kwak E, Michael M, et al. Identification of a small and
lethal subgroup of esophagogastric adenocarcinoma with evidence of
responsiveness to crizotinib by MET amplification. J Clin Oncol
2011;29(Suppl):Abstr 4130.
66. Chi A, Kwak E, Clark J, et al. Clinical improvement and rapid radio-
graphic regression induced by a MET inhibitor in a patient with MET-
amplified glioblastoma. J Clin Oncol 2011;29(Suppl):Abstr 2072.
67. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may
identify a subset of cancers with extreme sensitivity to the selective
tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006;
103:2316–2321.
68. Wu C, Tang Z, Fan W, et al. In vivo positron emission tomography
(PET) imaging of mesenchymal-epithelial transition (MET) receptor.
J Med Chem 2010;53:139–146.
Journal of Thoracic Oncology • Volume 7, Number 2, February 2012 Targeted MET Inhibition
Copyright © 2012 by the International Association for the Study of Lung Cancer 467
